Orchestra BioMed Announces Proposed Public Offering

Core Viewpoint - Orchestra BioMed Holdings, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the intention to use the proceeds for its AVIM therapy program, BACKBEAT study, and Virtue SAB program, among other corporate purposes [1][2]. Group 1: Offering Details - The offering includes common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the securities sold [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will fund the AVIM therapy program, the BACKBEAT study, the Virtue SAB program, and general corporate purposes [2]. Group 3: Company Overview - Orchestra BioMed is focused on accelerating high-impact biomedical technologies through partnerships with leading medical device companies [6]. - The company’s lead product candidate is AVIM therapy for hypertension, and it is also developing Virtue SAB for atherosclerotic artery disease [6]. - The company has strategic collaborations with Medtronic and Terumo for the development and commercialization of its key therapies [6].